FIGURE 3

FIGURE 3

Genomic location of DR5-AS and its expression in cisplatin-treated HeLa cells. (A) Schematic representation of DR5-AS (ENSG00000246130) and interference with DR5 transcript variant combined with the Ensembl structure. (B–D) qPCR analysis of DR5-AS expression in untreated cells (B, normalized to DR5-AS expression in HeLa cells), cisplatin-treated cells (C, normalized to DR5-AS expression in DMSO-treated cells), and fractionated cells (D). Cisplatin treatment and qPCR analyses were performed as explained in Figure 2B. Subcellular localization of DR5-AS was determined by qPCR analyses of nuclear and cytoplasmic RNAs isolated from cisplatin-treated HeLa cells. MALAT1 and GAPDH were used as markers for nuclear and cytoplasmic fractions, respectively. Ct values for the cytoplasmic and nuclear GAPDH were 9.7 and 13.9, respectively. Ct values for DR5-AS for the cytoplasmic and nuclear fractions were 25.2 and 20.8, respectively. p > 0.05, ^∗p ≤ 0.05, ^∗∗p ≤ 0.01, ^∗∗∗p ≤ 0.001, and ^****p ≤ 0.0001.